The agent storefront at https://agents.pubrio.com/llms.txt?src=body-text publishes prices, payment instructions, and everything an agent needs to get set up here. Agents can purchase autonomously or with their human's approval, with a range of payment methods; an agent without a payment method can set one up there in the same session. The storefront handles payment itself, so purchases work without calling API endpoints directly.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock on X. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
解鎖市場時間軸與訊號動態
過去 90 日內有 3 個訊號。
此公司進入各市場的次序 — 由最舊至最新
Director, International Indirect Tax
Director, International Indirect Tax
註冊以查看完整訊號動態
Scholar Rock 的國際擴張與競爭對手的比較
Scholar Rock你長條顯示所比較各公司之間的相對規模。
5 項指標| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Scholar Rock你 | 2 | 0 | +100% | 3 | 23 |
急速擴張 — 過去 90 日內開放了 23 個職位，較上一期上升 56%。 以 Clinical Systems 為主，集中於 美國。
Dublin, County Dublin, Ireland · 今日
Director, International Indirect Tax
Cambridge, MA · 3日前
Associate Director, IT Service Delivery & Support
Cambridge, MA · 3日前
Sr. Director, Infrastructure & Operations
整個技術架構共偵測到 34 項技術。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
過去 90 日內有 2 則提及。
Scholar Rock行政總裁David Hallal表示,公司正處於強勢地位,進入SMA社群的關鍵時期,生物製劑許可申請正在進行中。
Scholar Rock舉行2026年第二季度業績電話會議,高管討論業務更新、研發進展、商業準備和財務業績。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Scholar Rock 業務、市場及增長訊號的快速解答。
